Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Expert Recommendation for Standard MRI Protocol

The introduction of anti-amyloid therapies for Alzheimer’s disease (AD), such as lecanemab (Lequembi ®), which was recently approved in Korea, necessitates careful monitoring for amyloid-related imaging abnormalities (ARIA) using brain MRI. To optimize ARIA monitoring in Korean clinical settings,...

Full description

Saved in:
Bibliographic Details
Main Authors: Jimin Kim, Eunhee Kim, Mina Park, Yun Jung Bae, Chong Hyun Suh, Sung-Hye You, Younghee Yim, Ho-Joon Lee, Jin Wook Choi, Se Won Oh, Won-Jin Moon
Format: Article
Language:English
Published: The Korean Society of Radiology 2025-01-01
Series:Journal of the Korean Society of Radiology
Subjects:
Online Access:https://doi.org/10.3348/jksr.2024.0147
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832576361826353152
author Jimin Kim
Eunhee Kim
Mina Park
Yun Jung Bae
Chong Hyun Suh
Sung-Hye You
Younghee Yim
Ho-Joon Lee
Jin Wook Choi
Se Won Oh
Won-Jin Moon
author_facet Jimin Kim
Eunhee Kim
Mina Park
Yun Jung Bae
Chong Hyun Suh
Sung-Hye You
Younghee Yim
Ho-Joon Lee
Jin Wook Choi
Se Won Oh
Won-Jin Moon
author_sort Jimin Kim
collection DOAJ
description The introduction of anti-amyloid therapies for Alzheimer’s disease (AD), such as lecanemab (Lequembi ®), which was recently approved in Korea, necessitates careful monitoring for amyloid-related imaging abnormalities (ARIA) using brain MRI. To optimize ARIA monitoring in Korean clinical settings, the Korean Society of Neuroradiology (KSNR) and the Age and Neurodegeneration Imaging (ANDI) Study Group proposed MRI protocol recommendations on essential MR sequences, MRI acquisition parameters, timing and condition of MRI examinations, and essential details to provide a scientific basis for maximizing the safety and efficacy of AD treatment. A customized, standardized MRI protocol focusing on Korea’s healthcare environment can improve ARIA management and ensure patient safety through early detection of potential anti-amyloid therapy side effects, thereby enhancing treatment quality.
format Article
id doaj-art-b62d7fa0511743bf9e6c06f0e29ebddf
institution Kabale University
issn 2951-0805
language English
publishDate 2025-01-01
publisher The Korean Society of Radiology
record_format Article
series Journal of the Korean Society of Radiology
spelling doaj-art-b62d7fa0511743bf9e6c06f0e29ebddf2025-01-31T07:16:06ZengThe Korean Society of RadiologyJournal of the Korean Society of Radiology2951-08052025-01-018613444https://doi.org/10.3348/jksr.2024.0147Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Expert Recommendation for Standard MRI ProtocolJimin KimEunhee KimMina ParkYun Jung BaeChong Hyun SuhSung-Hye YouYounghee YimHo-Joon LeeJin Wook ChoiSe Won OhWon-Jin MoonThe introduction of anti-amyloid therapies for Alzheimer’s disease (AD), such as lecanemab (Lequembi ®), which was recently approved in Korea, necessitates careful monitoring for amyloid-related imaging abnormalities (ARIA) using brain MRI. To optimize ARIA monitoring in Korean clinical settings, the Korean Society of Neuroradiology (KSNR) and the Age and Neurodegeneration Imaging (ANDI) Study Group proposed MRI protocol recommendations on essential MR sequences, MRI acquisition parameters, timing and condition of MRI examinations, and essential details to provide a scientific basis for maximizing the safety and efficacy of AD treatment. A customized, standardized MRI protocol focusing on Korea’s healthcare environment can improve ARIA management and ensure patient safety through early detection of potential anti-amyloid therapy side effects, thereby enhancing treatment quality.https://doi.org/10.3348/jksr.2024.0147alzheimer’s diseaseamyloid-related imaging abnormalitiesanti-amyloid monoclonal antibodiesmagnetic resonance imagingmonitoring
spellingShingle Jimin Kim
Eunhee Kim
Mina Park
Yun Jung Bae
Chong Hyun Suh
Sung-Hye You
Younghee Yim
Ho-Joon Lee
Jin Wook Choi
Se Won Oh
Won-Jin Moon
Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Expert Recommendation for Standard MRI Protocol
Journal of the Korean Society of Radiology
alzheimer’s disease
amyloid-related imaging abnormalities
anti-amyloid monoclonal antibodies
magnetic resonance imaging
monitoring
title Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Expert Recommendation for Standard MRI Protocol
title_full Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Expert Recommendation for Standard MRI Protocol
title_fullStr Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Expert Recommendation for Standard MRI Protocol
title_full_unstemmed Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Expert Recommendation for Standard MRI Protocol
title_short Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Expert Recommendation for Standard MRI Protocol
title_sort amyloid related imaging abnormalities in anti amyloid monoclonal antibody therapy for alzheimer s disease expert recommendation for standard mri protocol
topic alzheimer’s disease
amyloid-related imaging abnormalities
anti-amyloid monoclonal antibodies
magnetic resonance imaging
monitoring
url https://doi.org/10.3348/jksr.2024.0147
work_keys_str_mv AT jiminkim amyloidrelatedimagingabnormalitiesinantiamyloidmonoclonalantibodytherapyforalzheimersdiseaseexpertrecommendationforstandardmriprotocol
AT eunheekim amyloidrelatedimagingabnormalitiesinantiamyloidmonoclonalantibodytherapyforalzheimersdiseaseexpertrecommendationforstandardmriprotocol
AT minapark amyloidrelatedimagingabnormalitiesinantiamyloidmonoclonalantibodytherapyforalzheimersdiseaseexpertrecommendationforstandardmriprotocol
AT yunjungbae amyloidrelatedimagingabnormalitiesinantiamyloidmonoclonalantibodytherapyforalzheimersdiseaseexpertrecommendationforstandardmriprotocol
AT chonghyunsuh amyloidrelatedimagingabnormalitiesinantiamyloidmonoclonalantibodytherapyforalzheimersdiseaseexpertrecommendationforstandardmriprotocol
AT sunghyeyou amyloidrelatedimagingabnormalitiesinantiamyloidmonoclonalantibodytherapyforalzheimersdiseaseexpertrecommendationforstandardmriprotocol
AT youngheeyim amyloidrelatedimagingabnormalitiesinantiamyloidmonoclonalantibodytherapyforalzheimersdiseaseexpertrecommendationforstandardmriprotocol
AT hojoonlee amyloidrelatedimagingabnormalitiesinantiamyloidmonoclonalantibodytherapyforalzheimersdiseaseexpertrecommendationforstandardmriprotocol
AT jinwookchoi amyloidrelatedimagingabnormalitiesinantiamyloidmonoclonalantibodytherapyforalzheimersdiseaseexpertrecommendationforstandardmriprotocol
AT sewonoh amyloidrelatedimagingabnormalitiesinantiamyloidmonoclonalantibodytherapyforalzheimersdiseaseexpertrecommendationforstandardmriprotocol
AT wonjinmoon amyloidrelatedimagingabnormalitiesinantiamyloidmonoclonalantibodytherapyforalzheimersdiseaseexpertrecommendationforstandardmriprotocol